{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:41:38Z","timestamp":1792510898008,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K22933 and 21H02946"],"award-info":[{"award-number":["20K22933 and 21H02946"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008667","name":"SENSHIN Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007263","name":"Astellas Foundation for Research on Metabolic Disorders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017102","name":"Friends of Leukemia Research Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017102","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>TNF receptor associated factor 6 (TRAF6) is an E3 ubiquitin ligase that has been implicated in myeloid malignancies. Although altered TRAF6 expression is observed in human acute myeloid leukemia (AML), its role in the AML pathogenesis remains elusive. In this study, we showed that the loss of TRAF6 in AML cells significantly impairs leukemic function in vitro and in vivo, indicating its functional importance in AML subsets. Loss of TRAF6 induces metabolic alterations, such as changes in glycolysis, TCA cycle, and nucleic acid metabolism as well as impaired mitochondrial membrane potential and respiratory capacity. In leukemic cells, TRAF6 expression shows a positive correlation with the expression of O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT), which catalyzes the addition of O-GlcNAc to target proteins involved in metabolic regulation. The restoration of growth capacity and metabolic activity in leukemic cells with TRAF6 loss, achieved through either forced expression of OGT or pharmacological inhibition of O-GlcNAcase (OGA) that removes O-GlcNAc, indicates the significant role of O-GlcNAc modification in the TRAF6-related cellular and metabolic dynamics. Our findings highlight the oncogenic function of TRAF6 in leukemia and illuminate the novel TRAF6\/OGT\/O-GlcNAc axis as a potential regulator of metabolic reprogramming in leukemogenesis.<\/jats:p>","DOI":"10.1038\/s41375-024-02245-3","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T05:01:35Z","timestamp":1712898095000},"page":"1032-1045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression"],"prefix":"10.1038","volume":"38","author":[{"given":"Shinichiro","family":"Matsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-5277","authenticated-orcid":false,"given":"Lyndsey C.","family":"Bolanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangmin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Shibamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagisa","family":"Oshima-Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4314-893X","authenticated-orcid":false,"given":"Shokichi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0664-7281","authenticated-orcid":false,"given":"Akihide","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5771-7462","authenticated-orcid":false,"given":"Daniel T.","family":"Starczynowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-1928","authenticated-orcid":false,"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2345-5572","authenticated-orcid":false,"given":"Tomoya","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"2245_CR1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"2245_CR2","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"2245_CR3","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"2245_CR4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/BS9.0000000000000015","volume":"1","author":"A Chen","year":"2019","unstructured":"Chen A, Hu S, Wang QF. Tumor heterogeneity of acute myeloid leukemia: insights from single-cell sequencing. Blood Sci. 2019;1:73\u201376.","journal-title":"Blood Sci"},{"key":"2245_CR5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.tcb.2019.03.003","volume":"29","author":"K Hinohara","year":"2019","unstructured":"Hinohara K, Polyak K. Intratumoral heterogeneity: more than just mutations. Trends Cell Biol. 2019;29:569\u201379.","journal-title":"Trends Cell Biol"},{"key":"2245_CR6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gde.2016.03.011","volume":"36","author":"S Li","year":"2016","unstructured":"Li S, Mason CE, Melnick A. Genetic and epigenetic heterogeneity in acute myeloid leukemia. Curr Opin Genet Dev. 2016;36:100\u20136.","journal-title":"Curr Opin Genet Dev"},{"key":"2245_CR7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400\u20134.","journal-title":"Nature"},{"key":"2245_CR8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/stem.2845","volume":"36","author":"L Busque","year":"2018","unstructured":"Busque L, Buscarlet M, Mollica L, Levine RL. Concise review: age-related clonal hematopoiesis: stem cells tempting the devil. Stem Cells. 2018;36:1287\u201394.","journal-title":"Stem Cells"},{"key":"2245_CR9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","volume":"24","author":"P Desai","year":"2018","unstructured":"Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018;24:1015\u201323.","journal-title":"Nat Med"},{"key":"2245_CR10","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","volume":"366","author":"S Jaiswal","year":"2019","unstructured":"Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366:eaan4673.","journal-title":"Science"},{"key":"2245_CR11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2183\/pjab.97.009","volume":"97","author":"M Yamamoto","year":"2021","unstructured":"Yamamoto M, Gohda J, Akiyama T, Inoue JI. TNF receptor-associated factor 6 (TRAF6) plays crucial roles in multiple biological systems through polyubiquitination-mediated NF-kappaB activation. Proc Jpn Acad Ser B Phys Biol Sci. 2021;97:145\u201360.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"2245_CR12","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1126\/science.1175065","volume":"325","author":"WL Yang","year":"2009","unstructured":"Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009;325:1134\u20138.","journal-title":"Science"},{"key":"2245_CR13","volume":"9","author":"SY Oh","year":"2021","unstructured":"Oh SY, Kang N, Kang JY, Kim KW, Choi JH, Yang YM, et al. Sestrin2 regulates osteoclastogenesis via the p62-TRAF6 interaction. Front Cell Dev Biol. 2021;9:646803.","journal-title":"Front Cell Dev Biol"},{"key":"2245_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11010-009-0315-y","volume":"338","author":"S Li","year":"2010","unstructured":"Li S, Lu K, Wang J, An L, Yang G, Chen H, et al. Ubiquitin ligase Smurf1 targets TRAF family proteins for ubiquitination and degradation. Mol Cell Biochem. 2010;338:11\u201317.","journal-title":"Mol Cell Biochem"},{"key":"2245_CR15","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","volume":"132","author":"L Barreyro","year":"2018","unstructured":"Barreyro L, Chlon TM, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018;132:1553\u201360.","journal-title":"Blood"},{"key":"2245_CR16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","volume":"133","author":"DA Sallman","year":"2019","unstructured":"Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133:1039\u201348.","journal-title":"Blood"},{"key":"2245_CR17","doi-asserted-by":"crossref","first-page":"e20201544","DOI":"10.1084\/jem.20201544","volume":"218","author":"JJ Trowbridge","year":"2021","unstructured":"Trowbridge JJ, Starczynowski DT. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. J Exp Med. 2021;218:e20201544.","journal-title":"J Exp Med"},{"key":"2245_CR18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/ni.3654","volume":"18","author":"J Fang","year":"2017","unstructured":"Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, et al. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nat Immunol. 2017;18:236\u201345.","journal-title":"Nat Immunol"},{"key":"2245_CR19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41590-020-0663-z","volume":"21","author":"Muto","year":"2020","unstructured":"Muto, Walker T, Choi CS, Hueneman K, Smith MA K, Gul Z, et al. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nat Immunol. 2020;21:535\u201345.","journal-title":"Nat Immunol"},{"key":"2245_CR20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.stem.2021.12.007","volume":"29","author":"T Muto","year":"2022","unstructured":"Muto T, Guillamot M, Yeung J, Fang J, Bennett J, Nadorp B, et al. TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022;29:298\u2013314.e299.","journal-title":"Cell Stem Cell"},{"key":"2245_CR21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.immuni.2013.05.012","volume":"38","author":"D Han","year":"2013","unstructured":"Han D, Walsh MC, Cejas PJ, Dang NN, Kim YF, Kim J, et al. Dendritic cell expression of the signaling molecule TRAF6 is critical for gut microbiota-dependent immune tolerance. Immunity. 2013;38:1211\u201322.","journal-title":"Immunity"},{"key":"2245_CR22","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature04980","volume":"442","author":"AV Krivtsov","year":"2006","unstructured":"Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818\u201322.","journal-title":"Nature"},{"key":"2245_CR23","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1021\/acs.analchem.8b02994","volume":"91","author":"K Sasaki","year":"2019","unstructured":"Sasaki K, Sagawa H, Suzuki M, Yamamoto H, Tomita M, Soga T, et al. Metabolomics platform with capillary electrophoresis coupled with high-resolution mass spectrometry for plasma analysis. Anal Chem. 2019;91:1295\u2013301.","journal-title":"Anal Chem"},{"key":"2245_CR24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"},{"key":"2245_CR25","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.celrep.2018.01.013","volume":"22","author":"J Fang","year":"2018","unstructured":"Fang J, Muto T, Kleppe M, Bolanos LC, Hueneman KM, Walker CS, et al. TRAF6 mediates basal activation of nf-kappab necessary for hematopoietic stem cell homeostasis. Cell Rep. 2018;22:1250\u201362.","journal-title":"Cell Rep"},{"key":"2245_CR26","doi-asserted-by":"crossref","first-page":"e99766","DOI":"10.15252\/embj.201899766","volume":"38","author":"X Ni","year":"2019","unstructured":"Ni X, Kou W, Gu J, Wei P, Wu X, Peng H, et al. TRAF6 directs FOXP3 localization and facilitates regulatory T-cell function through K63-linked ubiquitination. EMBO J. 2019;38:e99766.","journal-title":"EMBO J"},{"key":"2245_CR27","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.4049\/jimmunol.1202742","volume":"190","author":"JJ Xie","year":"2013","unstructured":"Xie JJ, Liang JQ, Diao LH, Altman A, Li Y. TNFR-associated factor 6 regulates TCR signaling via interaction with and modification of LAT adapter. J Immunol. 2013;190:4027\u201336.","journal-title":"J Immunol"},{"key":"2245_CR28","volume":"9","author":"S Xu","year":"2021","unstructured":"Xu S, Zhang X, Liu C, Liu Q, Chai H, Luo Y, et al. Role of mitochondria in neurodegenerative diseases: from an epigenetic perspective. Front Cell Dev Biol. 2021;9:688789.","journal-title":"Front Cell Dev Biol"},{"key":"2245_CR29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13668-3","volume":"11","author":"I Martinez-Reyes","year":"2020","unstructured":"Martinez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11:102.","journal-title":"Nat Commun"},{"key":"2245_CR30","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101761","volume":"23","author":"TN Seyfried","year":"2020","unstructured":"Seyfried TN, Arismendi-Morillo G, Mukherjee P, Chinopoulos C. On the origin of ATP synthesis in cancer. iScience. 2020;23:101761.","journal-title":"iScience"},{"key":"2245_CR31","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/cells8090967","volume":"8","author":"I Castro","year":"2019","unstructured":"Castro I, Sampaio-Marques B, Ludovico P. Targeting metabolic reprogramming in acute myeloid leukemia. Cells. 2019;8:967.","journal-title":"Cells"},{"key":"2245_CR32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ccell.2018.01.012","volume":"33","author":"T Yamauchi","year":"2018","unstructured":"Yamauchi T, Masuda T, Canver MC, Seiler M, Semba Y, Shboul M, et al. Genome-wide CRISPR-Cas9 screen identifies leukemia-specific dependence on a pre-mrna metabolic pathway regulated by DCPS. Cancer Cell. 2018;33:386\u2013400.e385.","journal-title":"Cancer Cell"},{"key":"2245_CR33","volume":"11","author":"D Fontana","year":"2020","unstructured":"Fontana D, Mauri M, Renso R, Docci M, Crespiatico I, Rost LM, et al. ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. Nat Commun. 2020;11:5938.","journal-title":"Nat Commun"},{"key":"2245_CR34","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108579","volume":"34","author":"K Murakami","year":"2021","unstructured":"Murakami K, Kurotaki D, Kawase W, Soma S, Fukuchi Y, Kunimoto H, et al. OGT regulates hematopoietic stem cell maintenance via PINK1-dependent mitophagy. Cell Rep. 2021;34:108579.","journal-title":"Cell Rep"},{"key":"2245_CR35","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.051911","volume":"143","author":"P Umapathi","year":"2021","unstructured":"Umapathi P, Mesubi OO, Banerjee PS, Abrol N, Wang Q, Luczak ED, et al. Excessive O-GlcNAcylation causes heart failure and sudden death. Circulation. 2021;143:1687\u2013703.","journal-title":"Circulation"},{"key":"2245_CR36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.tem.2013.02.002","volume":"24","author":"HB Ruan","year":"2013","unstructured":"Ruan HB, Singh JP, Li MD, Wu J, Yang X. Cracking the O-GlcNAc code in metabolism. Trends Endocrinol Metab. 2013;24:301\u20139.","journal-title":"Trends Endocrinol Metab"},{"key":"2245_CR37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10863-018-9742-3","volume":"50","author":"ZA Bacigalupa","year":"2018","unstructured":"Bacigalupa ZA, Bhadiadra CH, Reginato MJ. O-GlcNAcylation: key regulator of glycolytic pathways. J Bioenerg Biomembr. 2018;50:189\u201398.","journal-title":"J Bioenerg Biomembr"},{"key":"2245_CR38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nm.2054","volume":"16","author":"DT Starczynowski","year":"2010","unstructured":"Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010;16:49\u201358.","journal-title":"Nat Med"},{"key":"2245_CR39","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/cdd.2015.53","volume":"22","author":"T Soussi","year":"2015","unstructured":"Soussi T, Wiman KG. TP53: an oncogene in disguise. Cell Death Differ. 2015;22:1239\u201349.","journal-title":"Cell Death Differ"},{"key":"2245_CR40","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1101\/gad.191163.112","volume":"26","author":"H Hock","year":"2012","unstructured":"Hock H. A complex Polycomb issue: the two faces of EZH2 in cancer. Genes Dev. 2012;26:751\u20135.","journal-title":"Genes Dev"},{"key":"2245_CR41","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.20190250","volume":"216","author":"RC Skoda","year":"2019","unstructured":"Skoda RC, Schwaller J. Dual roles of EZH2 in acute myeloid leukemia. J Exp Med. 2019;216:725\u20137.","journal-title":"J Exp Med"},{"key":"2245_CR42","first-page":"5789","volume":"35","author":"M Cazzaniga","year":"2015","unstructured":"Cazzaniga M, Bonanni B. Relationship between metabolic reprogramming and mitochondrial activity in cancer cells. understanding the anticancer effect of metformin and its clinical implications. Anticancer Res. 2015;35:5789\u201396.","journal-title":"Anticancer Res"},{"key":"2245_CR43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40170-021-00253-w","volume":"9","author":"SB Panina","year":"2021","unstructured":"Panina SB, Pei J, Kirienko NV. Mitochondrial metabolism as a target for acute myeloid leukemia treatment. Cancer Metab. 2021;9:17.","journal-title":"Cancer Metab"},{"key":"2245_CR44","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1101\/gad.191056.112","volume":"26","author":"M Xiao","year":"2012","unstructured":"Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26:1326\u201338.","journal-title":"Genes Dev"},{"key":"2245_CR45","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature19353","volume":"537","author":"M Sciacovelli","year":"2016","unstructured":"Sciacovelli M, Goncalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature. 2016;537:544\u20137.","journal-title":"Nature"},{"key":"2245_CR46","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1074\/jbc.M115.688762","volume":"291","author":"T Laukka","year":"2016","unstructured":"Laukka T, Mariani CJ, Ihantola T, Cao JZ, Hokkanen J, Kaelin WG Jr., et al. Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. J Biol Chem. 2016;291:4256\u201365.","journal-title":"J Biol Chem"},{"key":"2245_CR47","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/ncb3209","volume":"17","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Qian X, Shen J, Wang Y, Li X, Liu R, et al. Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nat Cell Biol. 2015;17:1158\u201368.","journal-title":"Nat Cell Biol"},{"key":"2245_CR48","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.R114.577718","volume":"289","author":"Z Ma","year":"2014","unstructured":"Ma Z, Vosseller K. Cancer metabolism and elevated O-GlcNAc in oncogenic signaling. J Biol Chem. 2014;289:34457\u201365.","journal-title":"J Biol Chem"},{"key":"2245_CR49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fendo.2018.00415","volume":"9","author":"C Liu","year":"2018","unstructured":"Liu C, Li J. O-GlcNAc: a sweetheart of the cell cycle and DNA damage response. Front Endocrinol (Lausanne). 2018;9:415.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2245_CR50","volume":"6","author":"X Rao","year":"2015","unstructured":"Rao X, Duan X, Mao W, Li X, Li Z, Li Q, et al. O-GlcNAcylation of G6PD promotes the pentose phosphate pathway and tumor growth. Nat Commun. 2015;6:8468.","journal-title":"Nat Commun"},{"key":"2245_CR51","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/ncb3562","volume":"19","author":"T Wang","year":"2017","unstructured":"Wang T, Yu Q, Li J, Hu B, Zhao Q, Ma C, et al. O-GlcNAcylation of fumarase maintains tumour growth under glucose deficiency. Nat Cell Biol. 2017;19:833\u201343.","journal-title":"Nat Cell Biol"},{"key":"2245_CR52","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1093\/nar\/gkz537","volume":"47","author":"Y Meng","year":"2019","unstructured":"Meng Y, Liu C, Shen L, Zhou M, Liu W, Kowolik C, et al. TRAF6 mediates human DNA2 polyubiquitination and nuclear localization to maintain nuclear genome integrity. Nucleic Acids Res. 2019;47:7564\u201379.","journal-title":"Nucleic Acids Res"},{"key":"2245_CR53","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/hep.30801","volume":"71","author":"H Wu","year":"2020","unstructured":"Wu H, Yang TY, Li Y, Ye WL, Liu F, He XS, et al. Tumor necrosis factor receptor-associated factor 6 promotes hepatocarcinogenesis by interacting with histone deacetylase 3 to enhance c-Myc gene expression and protein stability. Hepatology. 2020;71:148\u201363.","journal-title":"Hepatology"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02245-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02245-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02245-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T10:12:08Z","timestamp":1714990328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02245-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2245"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02245-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"26 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.T.S. serves on the scientific advisory board at Kurome Therapeutics and is a consultant for and\/or received funding from Kurome Therapeutics, Captor Therapeutics, Treeline Biosciences, and Tolero Therapeutics. D.T.S. has equity in Kurome Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}